BlackRock Inc. grew its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,248,251 shares of the biopharmaceutical company’s stock after buying an additional 42,198 shares during the period. BlackRock Inc. owned 5.60% of Agios Pharmaceuticals worth $273,601,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Barrett Asset Management LLC purchased a new position in shares of Agios Pharmaceuticals during the 2nd quarter valued at $253,000. Principal Financial Group Inc. lifted its holdings in Agios Pharmaceuticals by 11.5% during the 1st quarter. Principal Financial Group Inc. now owns 14,895 shares of the biopharmaceutical company’s stock worth $1,218,000 after purchasing an additional 1,533 shares in the last quarter. NewSquare Capital LLC purchased a new stake in Agios Pharmaceuticals during the 2nd quarter worth about $182,000. State of Alaska Department of Revenue lifted its holdings in Agios Pharmaceuticals by 32.7% during the 2nd quarter. State of Alaska Department of Revenue now owns 5,960 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 1,470 shares in the last quarter. Finally, Xact Kapitalforvaltning AB lifted its holdings in Agios Pharmaceuticals by 13.0% during the 2nd quarter. Xact Kapitalforvaltning AB now owns 7,823 shares of the biopharmaceutical company’s stock worth $659,000 after purchasing an additional 900 shares in the last quarter. 93.64% of the stock is currently owned by hedge funds and other institutional investors.

AGIO has been the topic of a number of recent research reports. BidaskClub cut Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 26th. Piper Jaffray Companies reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Monday, June 4th. Canaccord Genuity reissued a “buy” rating and set a $90.00 price objective on shares of Agios Pharmaceuticals in a report on Wednesday, September 5th. Needham & Company LLC reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Thursday, August 2nd. Finally, SunTrust Banks reissued a “buy” rating and set a $123.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, July 23rd. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $97.90.

Shares of AGIO opened at $71.67 on Wednesday. The stock has a market cap of $4.26 billion, a P/E ratio of -10.62 and a beta of 1.78. Agios Pharmaceuticals Inc has a 52-week low of $51.62 and a 52-week high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.62) by $0.43. The business had revenue of $40.40 million for the quarter, compared to analyst estimates of $12.47 million. Agios Pharmaceuticals had a negative return on equity of 51.71% and a negative net margin of 462.08%. The company’s quarterly revenue was up 257.5% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.78) EPS. analysts expect that Agios Pharmaceuticals Inc will post -6.01 earnings per share for the current fiscal year.

In other Agios Pharmaceuticals news, Director John Maraganore sold 13,555 shares of the company’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $72.75, for a total value of $986,126.25. Following the transaction, the director now directly owns 38,609 shares in the company, valued at approximately $2,808,804.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott Biller sold 3,000 shares of the company’s stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $83.50, for a total value of $250,500.00. Following the completion of the transaction, the insider now owns 60,196 shares in the company, valued at $5,026,366. The disclosure for this sale can be found here. Insiders sold a total of 30,677 shares of company stock worth $2,412,335 over the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Recommended Story: Hedge Funds – How They Work For Investors

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals Inc (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.